Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

01.03.24 23:50 Uhr

Werte in diesem Artikel
Aktien

127,50 EUR -0,40 EUR -0,31%

Indizes

7.838,3 PKT 17,9 PKT 0,23%

4.268,5 PKT 8,1 PKT 0,19%

6.996,9 PKT -71,7 PKT -1,01%

2.714,7 PKT 7,8 PKT 0,29%

2.491,8 PKT -31,6 PKT -1,25%

937,6 PKT -14,0 PKT -1,47%

4.337,6 PKT 10,7 PKT 0,25%

Astrazeneca (AZN) closed at $64.60 in the latest trading session, marking a +0.69% move from the prior day. The stock lagged the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a rise of 0.23%, and the technology-dominated Nasdaq saw an increase of 1.14%.Shares of the pharmaceutical witnessed a loss of 4.02% over the previous month, trailing the performance of the Medical sector with its gain of 3.58% and the S&P 500's gain of 5.2%.The upcoming earnings release of Astrazeneca will be of great interest to investors. The company is expected to report EPS of $0.88, down 8.33% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $12.06 billion, indicating a 10.87% upward movement from the same quarter last year.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.06 per share and a revenue of $50.93 billion, indicating changes of +11.85% and +11.17%, respectively, from the former year.Investors should also take note of any recent adjustments to analyst estimates for Astrazeneca. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.52% lower. Astrazeneca is currently a Zacks Rank #3 (Hold).Valuation is also important, so investors should note that Astrazeneca has a Forward P/E ratio of 15.82 right now. This expresses a premium compared to the average Forward P/E of 14.9 of its industry.Meanwhile, AZN's PEG ratio is currently 1.18. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.67 at yesterday's closing price.The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 177, which puts it in the bottom 30% of all 250+ industries.The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf AstraZeneca

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu AstraZeneca PLC

Analysen zu AstraZeneca PLC

DatumRatingAnalyst
16.04.2024AstraZeneca HoldDeutsche Bank AG
15.04.2024AstraZeneca OverweightBarclays Capital
08.04.2024AstraZeneca OverweightBarclays Capital
05.04.2024AstraZeneca SellUBS AG
05.04.2024AstraZeneca OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
15.04.2024AstraZeneca OverweightBarclays Capital
08.04.2024AstraZeneca OverweightBarclays Capital
05.04.2024AstraZeneca OverweightJP Morgan Chase & Co.
04.04.2024AstraZeneca OverweightJP Morgan Chase & Co.
15.03.2024AstraZeneca OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
16.04.2024AstraZeneca HoldDeutsche Bank AG
16.02.2024AstraZeneca HoldJefferies & Company Inc.
12.02.2024AstraZeneca HaltenDZ BANK
08.02.2024AstraZeneca HoldJefferies & Company Inc.
30.01.2024AstraZeneca HoldDeutsche Bank AG
DatumRatingAnalyst
05.04.2024AstraZeneca SellUBS AG
28.03.2024AstraZeneca SellDeutsche Bank AG
25.03.2024AstraZeneca SellUBS AG
19.03.2024AstraZeneca SellUBS AG
15.03.2024AstraZeneca SellDeutsche Bank AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AstraZeneca PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"